Cipro Warning.pdf

CIPRO is a fluoroquinolone antibacterial for oral use, with initial US approval in 1987, and has serious adverse reaction warnings including tendinitis, tendon rupture, peripheral neuropathy, central nervous system effects, and exacerbation of myasthenia gravis. It is indicated for various infections, including skin and skin structure, bone and joint, intra-abdominal, and urinary tract infections, with specific dosage guidelines for adults and pediatrics. Contraindications include known hypersensitivity to CIPRO or other quinolones and concomitant administration with tizanidine. Warnings and precautions include hypersensitivity and other serious reactions, hepatotoxicity, and QT prolongation. Common adverse reactions include nausea, diarrhea, and liver function tests abnormal. Drug interactions include theophylline, warfarin, antidiabetic agents, and multivalent cation-containing products.